Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kintor Pharmaceutical Ltd has announced the successful enrollment of the first participant in their Phase II clinical trial in China for GT20029, a novel acne treatment. GT20029, developed by Kintor’s in-house platform, is a topical androgen receptor targeting compound and marks a global first in reaching this stage of clinical testing. The trial is a multi-center, double-blind study aimed at evaluating the compound’s efficacy and safety, building on prior positive Phase I results for both acne and androgenetic alopecia.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.